Abstracts tagged "medication and risk"

Abstract Number: 2785 • 2019 ACR/ARP Annual Meeting
Cancer Risk in a Large Inception SLE Cohort: Effects of Age, Smoking, and Medications
Sasha Bernatsky¹, Rosalind Ramsey-Goldman ², Murray Urowitz ³, John Hanly ⁴, Caroline Gordon ⁵, Michelle Petri ⁶, Ellen M Ginzler ⁷, Daniel J Wallace ⁸, Sang-Cheol Bae ⁹, Juanita Romero-Diaz ¹⁰, MA Dooley ¹¹, Christine Peschken ¹², David A Isenberg ¹³, Anisur Rahman ¹⁴, Susan Manzi ¹⁵, Soren Jacobsen ¹⁶, S Sam Lim ¹⁷, Ronald F Van Vollenhoven ¹⁸, Ola Nived ¹⁹, Diane Kamen ²⁰, Cynthia Aranow ²¹, Jill Buyon ²², Guillermo Ruiz-Irastorza ²³, Ian Bruce ²⁴, Dafna Gladman ²⁵, Paul Fortin ²⁶, Joan T. Merrill ²⁷, Jorge Sanchez-Guerrero ²⁸, Kenneth C Kalunian ²⁹, Kristjan Steinsson ³⁰, Manuel Ramos ³¹, Asad Zoma ³², Thomas Stoll ³³, Munther A Khamashta ³⁴, Murat Inanc ³⁵ and Ann E Clarke ³⁶, ¹Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²Northwestern University, Chicago, IL, ³University Health Network, University of Toronto, Toronto, ON, Canada, ⁴Queen Elizabeth II Health Science Centre (Nova Scotia Rehab Site), Halifax, NS, Canada, ⁵University of Birmingham, Birmingham, United Kingdom, ⁶Johns Hopkins University School of Medicine, Baltimore, MD, ⁷State University of New York Downstate Medical Center, Brooklyn, NY, ⁸Cedars-Sinai Medical Centre, Beverly Hills, CA, ⁹Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ¹⁰Instituto Nacional de Ciencias Medicas y Nutricion Salvador, Zubiran Vasco de Quiroga, Mexico City, Mexico, ¹¹UnC Kidney Centre, Chapel Hill, NC, ¹²University of Manitoba, Winnipeg, Canada, ¹³Centre for Rheumatology, London, United Kingdom, ¹⁴University College London, London, United Kingdom, ¹⁵Allegheny Health Network, Pittsburg, PA, ¹⁶Copenhagen Lupus and Vasculitis Clinic, Copenhagen, Denmark, ¹⁷Emory University, Atlanta, GA, ¹⁸Amsterdam Rheumatology & Immunology Center, Amsterdam, Netherlands, ¹⁹Lund University, Lund, Sweden, ²⁰Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA., Charleston, SC, ²¹Feinstein Institute for Medical Research, Manhasset, NY, ²²NYU School of Medicine, New York, ²³Autoimmune Diseases Unit, Hospital Universitario Cruces, Barakaldo, Spain, Barakaldo, Spain, ²⁴University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom, ²⁵Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ²⁶Division de Rhumatologie, Département de Médecine, CHU de Québec – Université Laval, Axe maladies infectieuses et inflammatoires, Centre de recherche du CHU de Québec – Université Laval, Canada, Quebec, QC, Canada, ²⁷Okalahoma Medical Research Foundation, Oklahoma City, OK, ²⁸Toronto Western Hospital, Toronto, ON, Canada, ²⁹UC San Diego School of Medicine, LaJolla, CA, ³⁰Landspitali, University Hospital, Reykjavik, Iceland, ³¹Department of Internal Medicine, Hospital Nuestra Señora del Prado, Talavera, Talavera, Spain, Talavera, Spain, ³²Lanarkshire Centre for Rheumatology, Hairmyres Hospital, East Kilbride, Scotland, United Kingdom, ³³University of Glasgow, Kilbride, Scotland, United Kingdom, ³⁴King's College London School of Medicine, London, United Kingdom, ³⁵Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ³⁶University of Calgary, Calgary, AB, Canada
Background/Purpose: Many studies of cancer risk in SLE are limited by small sample size or use of administrative data, which rely on billing code diagnoses…
Abstract Number: 1535 • 2018 ACR/ARHP Annual Meeting
Enhancing Patient Ability to Process and Use Information about Medication Risks and Benefits
Genevieve Hickey¹, Caprice Hunt¹, Molly Keebler², Delesha M. Carpenter³, Elizabeth (Blair) Solow⁴, Valerie Reyna⁵, W. Benjamin Nowell⁶, Cynthia Edmonds¹, Kimberlee O'Neill¹ and Susan J. Blalock¹, ¹Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, ²Center for BrainHealth, University of Texas Dallas, Dallas, TX, ³Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Asheville, NC, ⁴UT Southwestern Rheumatology, Dallas, TX, ⁵Cornell University, Ithica, NY, ⁶Global Healthy Living Foundation, Upper Nyack, NY
Background/Purpose: Guidelines for the treatment of rheumatoid arthritis (RA) underscore the importance of an early and targeted approach to control inflammation. However, patients are often…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].